Ral A CRISPR Activation Plasmid (h): sc-403983-ACT

RALA encodes the small GTPase RalA, a Ras-like molecular switch that cycles between GDP- and GTP-bound states to coordinate vesicle trafficking, exocytosis, and actin cytoskeleton remodeling. Through RalGEF-dependent signaling, RalA engages effectors such as the exocyst complex and RalBP1 to regulate membrane dynamics, receptor recycling, and cell polarity. RalA activity integrates with Ras/MAPK and PI3K-associated networks, linking growth factor cues to changes in migration, adhesion, and proliferation. Dysregulated RalA signaling has been associated with altered invasive behavior and oncogenic pathway output in multiple cancer contexts, making it a useful node for studying Ras effector branch specificity and membrane trafficking phenotypes.

Ral A CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous RALA expression without altering the underlying DNA sequence.

Ral A CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the RALA locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the RALA transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Ral A expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native RALA locus and enabling the study of Ral A-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Ral A pathway restoration in tumor cells with silenced or reduced RALA expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.